Results 161 to 170 of about 110,023 (239)

Awareness of HPV, HPV vaccine and associated factors among male junior high school students in Zhejiang Province, China. [PDF]

Front Public Health
Zhao X, Zhang X, Xu Y, Huang Y, Wang L, Lv Q, Wu S.   +6 more
europepmc   +1 more source

Voice of Asia: Provision of Patient‐Centered Care in Oral Cavity Cancer: A Qualitative Study With Patients, Caregivers, and Healthcare Professionals in Five Asia‐Pacific Regions

Asia-Pacific Journal of Clinical Oncology, EarlyView.
The study identified key barriers to optimal patient‐centered care, including delayed diagnosis due to awareness and stigma‐related barriers among patients and caregivers, and opportunities to enhance multidisciplinary coordination. Resource limitations impacted nursing and psychosocial support, while access to support care varied across regions.
Edwin Pun Hui, Puma Sundaresan, Hye Ryun Kim, Khoi Tuan Nguyen, Tracey E Nicholls, Hai‐Ling Teng, Yu‐Chung Li, Ying Jie Yew, Regina Gowindah, Con Stylianou, Pei‐Jen Lou   +10 more
wiley   +1 more source

Detection of human papillomavirus (HPV)-specific T cell response in women with low-grade cervical intraepithelial lesion and HPV vaccinated subjects. [PDF]

Front Immunol
Zelini P, Zavaglio F, Dominioni M, Valsecchi M, Lo Grasso L, d'Angelo P, Giardina F, Romano G, Paolucci S, Lilleri D, Cassaniti I, Spinillo A, Baldanti F, Gardella B.   +13 more
europepmc   +1 more source

Accuracy of human papillomavirus testing in detecting persistent or recurrent disease at follow‐up after conization

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Using HPV testing and margin status alone as predictors of CIN1+ persistence/recurrence is as effective as the standard co‐test. This highlights the significance of HPV status compared to the co‐test post‐conization and indicates that HPV testing alone could be an effective follow‐up strategy for women with negative margins.
Ghina Alaref, Lone Kjeld Petersen
wiley   +1 more source

Investigation of the presence of cervical human papillomavirus and the distribution of preinvasive lesions in patients using immunomodulators-Inosine Pranobex. [PDF]

Infect Agent Cancer
Özdemir BG, Safarova G, Yıldırım O, Aslan M, Avcı F, Bilgi A, Çelik Ç.   +6 more
europepmc   +1 more source

Liminal Bioethics for Liminal Statuses: A New Method for Analysing Novel Biological Entities

Bioethics, EarlyView.
ABSTRACT Novel biological entities such as cell lines and organoids do not typically fit into established conceptual categories, such as ‘human’ or ‘nonhuman’, ‘gift’ or ‘property’. This makes developing robust ethical principles or policy solutions difficult.
Michael Wee, Ilina Singh
wiley   +1 more source

The R2TP complex stabilises E7 to drive human papillomavirus-mediated pathogenesis in cellular models of cervical cancer. [PDF]

Virol J
Shadang M, Arumugam A, Singh DK, Keshari P, Mathur S, Iyer VK, Singhal S, Chauhan SS, Akhter Q, Mir RA.   +9 more
europepmc   +1 more source

The Australian Penile Cancer Clinical Registry: a comprehensive national approach to data collection

BJU International, EarlyView.
Background Penile cancer is a rare malignancy, with an Australian incidence of 0.6 in 100 000 men, with a wide range of clinical presentations, from localised, curable tumours to aggressive forms with high morbidity and mortality. Epidemiological data and management guidelines for penile cancer in Australia are limited.
Henry Y.C. Pan, David Homewood, Harrison Lucas, Brendan Dittmer, Jiasian Teh, Jonathan S. O'Brien, Jianliang Liu, Ben Tran, Justin Chee, James A. Churchill, Nathan Lawrentschuk, Niall M. Corcoran   +11 more
wiley   +1 more source

One-pot CRISPR-based point of care platform for rapid, specific and sensitive detection of HPV 16 without pre-amplification. [PDF]

Microsyst Nanoeng
Chen Y, Chen Y, Zhang C, Cai Y, Zeng Z, Reboud J, Cooper JM, Shan H, Wang Y, Xu G.   +9 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source